Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy

Kubo,Makoto; Satoh,Takefumi; Ishiyama,Hiromichi; Tabata,Ken-Ichi; Tsumura,Hideyasu; Komori,Shoko; Iwamura,Masatsugu; Baba,Shiro; Hayakawa,Kazushige; Kawamura,Toshihiko; Obata,Fumiya

doi:10.3892/or.2017.6095

January-2018 Volume 39 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2018 Volume 39 Issue 1

Full Size Image

Article

Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy

Authors:
- Makoto Kubo
- Takefumi Satoh
- Hiromichi Ishiyama
- Ken-Ichi Tabata
- Hideyasu Tsumura
- Shoko Komori
- Masatsugu Iwamura
- Shiro Baba
- Kazushige Hayakawa
- Toshihiko Kawamura
- Fumiya Obata
View Affiliations / Copyright

Affiliations: Division of Immunology, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa 252-0373, Japan, Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0373, Japan, Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0373, Japan
Pages: 417-424
|
Published online on: November 13, 2017

https://doi.org/10.3892/or.2017.6095
Expand metrics +

Abstract

Radiotherapy (RT) is one of the most important treatments for prostate cancer. Although RT can kill cancer cells through direct and indirect effects of radiation, it occasionally induces an abscopal effect whereby localized radiation treatment is associated with elimination of metastatic cancer at a distance from the irradiated area. Thus, RT may induce an effective antitumor immune response, although the mechanism involved has remained unclear. The present was designed to evaluate this effect of RT in 36 patients with prostate cancer who provided informed consent prior to enrollment in this clinical trial. Peripheral blood samples were collected periodically after low-dose-rate (LDR) prostate brachytherapy, and lymphocyte subsets were analyzed by flow cytometry. The proportion of activated T cells (CD3+HLA-DR+, CD4+HLA-DR+ and CD8+HLA-DR+) in peripheral blood revealed a gradual and bimodal increase after LDR brachytherapy, whereas memory CD8+ T cells bimodally decreased after treatment. The ratios of activated T cells and regulatory T cells gradually increased after the treatment. Thus, LDR brachytherapy was demonstrated to induce effective immune responses in patients. This increase of activated T cells may contribute to maintenance of remission and reduction of relapse rates.

View Figures

View References

1	Ishiyama H, Satoh T, Kawakami S, Tsumura H, Komori S, Tabata K, Sekiguchi A, Takahashi R, Soda I, Takenaka K, et al: A prospective quasi-randomized comparison of intraoperatively built custom-linked seeds versus loose seeds for prostate brachytherapy. Int J Radiat Oncol Biol Phys. 90:134–139. 2014. View Article : Google Scholar : PubMed/NCBI
2	Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al: Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 520:373–377. 2015. View Article : Google Scholar : PubMed/NCBI
3	Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, et al: Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res. 13:1493–1502. 2007. View Article : Google Scholar : PubMed/NCBI
4	Schaue D, Comin-Anduix B, Ribas A, Zhang L, Goodglick L, Sayre JW, Debucquoy A, Haustermans K and McBride WH: T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res. 14:4883–4890. 2008. View Article : Google Scholar : PubMed/NCBI
5	Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H and Nishimura T: Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: Its potentiation by combination with Th1 cell therapy. Cancer Res. 70:2697–2706. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, et al: Chemotherapy and radiotherapy: Cryptic anticancer vaccines. Semin Immunol. 22:113–124. 2010. View Article : Google Scholar : PubMed/NCBI
7	Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S and Hodge JW: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 5:403–416. 2014. View Article : Google Scholar : PubMed/NCBI
8	Stone HB, Peters LJ and Milas L: Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst. 63:1229–1235. 1979.PubMed/NCBI
9	Yoshimoto Y, Suzuki Y, Mimura K, Ando K, Oike T, Sato H, Okonogi N, Maruyama T, Izawa S, Noda SE, et al: Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One. 9:e925722014. View Article : Google Scholar : PubMed/NCBI
10	Ludgate CM: Optimizing cancer treatments to induce an acute immune response: Radiation abscopal effects, PAMPs, and DAMPs. Clin Cancer Res. 18:4522–4525. 2012. View Article : Google Scholar : PubMed/NCBI
11	Marabelle A, Filatenkov A, Sagiv-Barfi I and Kohrt H: Radiotherapy and toll-like receptor agonists. Semin Radiat Oncol. 25:34–39. 2015. View Article : Google Scholar : PubMed/NCBI
12	Fernández-García EM, Vera-Badillo FE, Perez-Valderrama B, Matos-Pita AS and Duran I: Immunotherapy in prostate cancer: Review of the current evidence. Clin Transl Oncol. 17:339–357. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH and Schaue D: Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys. 81:1128–1135. 2011. View Article : Google Scholar : PubMed/NCBI
14	Wu CT, Chen MF, Chen WC and Hsieh CC: The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 8:159–169. 2013. View Article : Google Scholar : PubMed/NCBI
15	Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W and Wu L: CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73:2782–2794. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tabi Z, Spary LK, Coleman S, Clayton A, Mason MD and Staffurth J: Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. J Immunol. 185:1330–1339. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8

Figure 9

Related Articles